Reversal Agents for Oral Antiplatelet and Anticoagulant Treatment During Bleeding Events: Current Strategies.

Raimondi, Peter; Hylek, Elaine M; Aronis, Konstantinos N

Raimondi, Peter; Hylek, Elaine M; Aronis, Konstantinos N.

Affiliation

Raimondi P; Department of Medicine, Boston Medical Center, Boston University, Boston MA, United States.
Hylek EM; Section of General Internal Medicine, Department of Medicine, Boston Medical Center, Boston University, Boston MA, United States.
Aronis KN; Johns Hopkins Hospital, Division of Cardiology, 1800 Orleans Street, Zayed 7125, Baltimore, MD 21287, United States.

Curr Pharm Des ; 23(9): 1406-1423, 2017.

Article in En | MEDLINE | ID: mdl-27917717

Subject(s)

Anticoagulants/therapeutic use; Hemorrhage/drug therapy; Platelet Aggregation Inhibitors/therapeutic use; Administration, Oral; Anticoagulants/administration & dosage; Cardiovascular Diseases/complications; Cardiovascular Diseases/drug therapy; Hemorrhage/complications; Humans; Platelet Aggregation Inhibitors/administration & dosage

Key words

Antiplatelets; andexanet alfa; anticoagulants; antidotes; aripazine; idarucizumab; non-vitamin K oral anticoagulants; reversal; warfarin

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Platelet Aggregation Inhibitors / Hemorrhage / Anticoagulants Type of study: Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Curr Pharm Des Journal subject: FARMACIA Year: 2017 Document type: Article Affiliation country: United States Country of publication: United Arab Emirates

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google